CSPC Pharmaceutical Group
Logotype for CSPC Pharmaceutical Group Limited

CSPC Pharmaceutical Group (1093) investor relations material

CSPC Pharmaceutical Group Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for CSPC Pharmaceutical Group Limited
Q3 2026 earnings summary18 Nov, 2026

Executive summary

  • 9M 2026 revenue rose 27.0% YoY to RMB25,260M, including RMB6,268M of licence-fee income; reported profit attributable to shareholders increased 101.5% to RMB7,076M.

  • Q3 revenue rose 0.7% YoY to RMB6,665M; finished-drug revenue excluding BD income grew 10.1% to RMB5,215M.

  • Gross profit increased 27.0% to RMB18,598M and gross margin rose 8.0pp to 73.6%.

Financial highlights

  • 9M underlying profit, excluding FVTPL fair-value changes and share-based compensation, increased 134.5% to RMB7,220M; basic and diluted EPS were RMB62.14 and RMB61.99 cents, up 102.3% and 101.8%.

  • Profit before tax was RMB8,756M versus RMB4,303M; profit for the period was RMB7,446M versus RMB3,536M.

  • 9M R&D expenses rose 10.9% to RMB4,643M, equal to 24.4% of revenue excluding BD income; selling expenses were RMB4,919M, or 25.9% on that basis.

  • Q3 reported profit attributable to shareholders rose 1.9% to RMB982M; R&D expenses increased 7.4% to RMB1,614M, while selling expenses fell 6.9% to RMB1,628M.

Segment performance

  • Finished-drug revenue rose 40.1% to RMB21,648M, including RMB6,268M in licence fees; product sales excluding licence fees grew 10.6%.

  • Nervous-system finished-drug sales increased 29.1% to RMB7,318M; digestion and metabolism sales rose 14.2% to RMB887M.

  • Bulk products revenue fell 22.3% to RMB2,336M; Vitamin C sales declined 18.9% to RMB1,451M and antibiotics fell 27.3% to RMB885M.

  • Functional food and other revenue decreased 11.1% to RMB1,276M, reflecting lower sales volume and prices for anhydrous glucose and caffeine.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next CSPC Pharmaceutical Group earnings date

Logotype for CSPC Pharmaceutical Group Limited
Q4 202625 Mar, 2027
CSPC Pharmaceutical Group
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next CSPC Pharmaceutical Group earnings date

Logotype for CSPC Pharmaceutical Group Limited
Q4 202625 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

CSPC Pharmaceutical Group Limited is a China-based pharmaceutical company engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company operates through multiple segments, including finished drugs, bulk drug manufacturing, and innovative drug development. Its product portfolio spans a range of therapeutic areas such as cardiovascular, oncology, anti-infectives, and central nervous system disorders. The company is headquartered in Shijiazhuang, China, and its shares are listed on the HKEX.